192 related articles for article (PubMed ID: 15167059)
61. [Leukodystrophies--loss of myelin leads to severe disabilities].
Schenk M
Dtsch Med Wochenschr; 2010 Oct; 135(41):p36. PubMed ID: 20949415
[No Abstract] [Full Text] [Related]
62. [Primary adrenal insufficiency as the form of onset of adrenoleukodystrophy in a 4-year-old boy].
Tornero Patricio S; de la Vega JA; Nehme Alvarez D; Gentil González FJ; Lluch Fernández MD; González Hachero J
Endocrinol Nutr; 2009 Jan; 56(1):40-2. PubMed ID: 19627707
[TBL] [Abstract][Full Text] [Related]
63. Lipoid pneumonia as a complication of Lorenzo's oil therapy in a patient with adrenoleukodystrophy.
Majori M; Scarascia A; Anghinolfi M; Pisi R; Gnetti L; Casalini AG
J Bronchology Interv Pulmonol; 2014 Jul; 21(3):271-3. PubMed ID: 24992138
[TBL] [Abstract][Full Text] [Related]
64. [Diet therapy in the treatment of neuropediatric disorders].
Chaves-Carballo E
Rev Neurol; 2003 Aug 1-15; 37(3):267-74. PubMed ID: 12938059
[TBL] [Abstract][Full Text] [Related]
65. The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy.
Deon M; Wajner M; Sirtori LR; Fitarelli D; Coelho DM; Sitta A; Barschak AG; Ferreira GC; Haeser A; Giugliani R; Vargas CR
J Neurol Sci; 2006 Sep; 247(2):157-64. PubMed ID: 16750542
[TBL] [Abstract][Full Text] [Related]
66. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy.
van Geel BM; Bezman L; Loes DJ; Moser HW; Raymond GV
Ann Neurol; 2001 Feb; 49(2):186-94. PubMed ID: 11220738
[TBL] [Abstract][Full Text] [Related]
67. Management of X-linked adrenoleukodystrophy in Morocco: actual situation.
Benjelloun FZM; Kriouile Y; Cheillan D; Daoud-Tetouani H; Chabraoui L
BMC Res Notes; 2017 Nov; 10(1):567. PubMed ID: 29116030
[TBL] [Abstract][Full Text] [Related]
68. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy.
Shapiro E; Krivit W; Lockman L; Jambaqué I; Peters C; Cowan M; Harris R; Blanche S; Bordigoni P; Loes D; Ziegler R; Crittenden M; Ris D; Berg B; Cox C; Moser H; Fischer A; Aubourg P
Lancet; 2000 Aug; 356(9231):713-8. PubMed ID: 11085690
[TBL] [Abstract][Full Text] [Related]
69. Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo oil.
Kaplan PW; Tusa RJ; Shankroff J; Heller J; Moser HW
Ann Neurol; 1993 Aug; 34(2):169-74. PubMed ID: 8338341
[TBL] [Abstract][Full Text] [Related]
70. Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid--a case report.
Terre'Blanche G; van der Walt MM; Bergh JJ; Mienie LJ
Lipids Health Dis; 2011 Aug; 10():152. PubMed ID: 21871076
[TBL] [Abstract][Full Text] [Related]
71. Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.
Pour RB; Stöckler-Ipsiroglu S; Hunneman DH; Gahr M; Korenke GC; Pabst W; Hanefeld F; Peters A
J Inherit Metab Dis; 2000 Mar; 23(2):113-9. PubMed ID: 10801052
[TBL] [Abstract][Full Text] [Related]
72. Adrenoleukodystrophy: clinical analysis of 9 Taiwanese children.
Liang JS; Lee WT; Hwu WL; Peng SS; Chu LW; Wang PJ; Shen YZ
Acta Paediatr Taiwan; 2004; 45(5):272-7. PubMed ID: 15868809
[TBL] [Abstract][Full Text] [Related]
73. [Adrenoleukodystrophy--clinical, biochemical and therapeutic aspects].
Skjeldal OH; Strømme P; Christensen E
Tidsskr Nor Laegeforen; 1994 Nov; 114(28):3321-3. PubMed ID: 7809891
[TBL] [Abstract][Full Text] [Related]
74. Lorenzo's oil.
Moser HW
Lancet; 1993 Feb; 341(8844):544. PubMed ID: 8094785
[No Abstract] [Full Text] [Related]
75. Adrenoleukodystrophy: phenotypic variability and implications for therapy.
Moser HW; Moser AB; Smith KD; Bergin A; Borel J; Shankroff J; Stine OC; Merette C; Ott J; Krivit W
J Inherit Metab Dis; 1992; 15(4):645-64. PubMed ID: 1528023
[TBL] [Abstract][Full Text] [Related]
76. A Japanese family with adrenoleukodystrophy with a codon 291 deletion: a clinical, biochemical, pathological, and genetic report.
Kano S; Watanabe M; Kanai M; Koike R; Onodera O; Tsuji S; Okamoto K; Shoji M
J Neurol Sci; 1998 Jun; 158(2):187-92. PubMed ID: 9702690
[TBL] [Abstract][Full Text] [Related]
77. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes.
Mahmood A; Dubey P; Moser HW; Moser A
Pediatr Transplant; 2005 Dec; 9 Suppl 7():55-62. PubMed ID: 16305618
[TBL] [Abstract][Full Text] [Related]
78. Two novel mutations in the adrenoleukodystrophy gene in two unrelated Japanese families and the long-term effect of bone marrow transplantation.
Ohi T; Takechi S; Itokazu N; Shiomi K; Sugimoto S; Antoku Y; Kato K; Sugimoto T; Nakayama T; Matsukura S
J Neurol Sci; 2000 Aug; 177(2):131-8. PubMed ID: 10980309
[TBL] [Abstract][Full Text] [Related]
79. Metabolic disorders in children.
Morris AA; Turnbull DM
Curr Opin Neurol; 1994 Dec; 7(6):535-41. PubMed ID: 7866586
[TBL] [Abstract][Full Text] [Related]
80. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil).
Rasmussen M; Moser AB; Borel J; Khangoora S; Moser HW
Neurochem Res; 1994 Aug; 19(8):1073-82. PubMed ID: 7800117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
